MPN

Myelofibrosis

- IRB# 16363
  - Phase 2 INCBO50465 plus Ruxolitinib

- IRB# 19142
  - Open-Label, Ph 2a/2b of INCB050465 plus Ruxolitinib in Subjects with Primary Myelofibrosis (MF), Post-Polycythemia Vera MF, or Post-Essential Thrombocythemia MF who have failed prior treatment with a JAK Inhibitor

Systemic Mastocytosis

- IRB# 17155
  - Phase 1 of DCC-2618 in Advanced Malignancies

Polycythemia vera

- IRB# 19144
  - 2-Part, Randomized, Open-label, Ph 2a/2b of KRT-232 Compared to Ruxolitinib in Phlebotomy-Dependent Polycythemia Vera

Non Treatment

- IRB# 15977
  - Non Treatment National MDS Study (ECOG/ACRIN)

Cross Disease Trial

http://www.ohsu.edu/research/rda/so/knight.php